These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 39019203)

  • 1. Stellarex Drug-Coated Balloon for the Treatment of Peripheral Artery Disease: Five-Year Results from the ILLUMENATE Pivotal Randomized Controlled Trial.
    Krishnan P; Faries P; Niazi K; Sachar R; Jain A; Brodmann M; Werner M; Holden A; Tarricone A; Tarra T; Lyden S
    Am J Cardiol; 2024 Sep; 227():83-90. PubMed ID: 39019203
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Stellarex Drug-Coated Balloon for Treatment of Femoropopliteal Disease: Twelve-Month Outcomes From the Randomized ILLUMENATE Pivotal and Pharmacokinetic Studies.
    Krishnan P; Faries P; Niazi K; Jain A; Sachar R; Bachinsky WB; Cardenas J; Werner M; Brodmann M; Mustapha JA; Mena-Hurtado C; Jaff MR; Holden AH; Lyden SP
    Circulation; 2017 Sep; 136(12):1102-1113. PubMed ID: 28729250
    [TBL] [Abstract][Full Text] [Related]  

  • 3. No Mortality Signal With Stellarex Low-Dose Paclitaxel DCB: ILLUMENATE Pivotal 4-Year Outcomes.
    Lyden SP; Faries PL; Niazi KAK; Sachar R; Jain A; Brodmann M; Werner M; Sood A; Krishnan P
    J Endovasc Ther; 2022 Dec; 29(6):929-936. PubMed ID: 35000470
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Four-year patient-level pooled mortality analysis of the ILLUMENATE US Pivotal and EU randomized controlled trials.
    Lyden SP; Brodmann M; Parikh SA; Krishnan P; Schroeder H; Werner M; Holden A; Ouriel K; Tarra T; Gray WA
    J Vasc Surg; 2022 Feb; 75(2):600-607. PubMed ID: 34506898
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Low-Dose Paclitaxel-Coated Versus Uncoated Percutaneous Transluminal Balloon Angioplasty for Femoropopliteal Peripheral Artery Disease: One-Year Results of the ILLUMENATE European Randomized Clinical Trial (Randomized Trial of a Novel Paclitaxel-Coated Percutaneous Angioplasty Balloon).
    Schroeder H; Werner M; Meyer DR; Reimer P; Krüger K; Jaff MR; Brodmann M;
    Circulation; 2017 Jun; 135(23):2227-2236. PubMed ID: 28424223
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Five-Year Independent Patient-Level Mortality Analysis of the Pooled ILLUMENATE Pivotal and EU Randomized Controlled Trials.
    Lyden SP; Brodmann M; Schroeder H; Holden A; Ouriel K; Tarra TR; Gray WA
    J Soc Cardiovasc Angiogr Interv; 2023; 2(4):100634. PubMed ID: 39131660
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mortality Assessment of Paclitaxel-Coated Balloons: Patient-Level Meta-Analysis of the ILLUMENATE Clinical Program at 3 Years.
    Gray WA; Jaff MR; Parikh SA; Ansel GM; Brodmann M; Krishnan P; Razavi MK; Vermassen F; Zeller T; White R; Ouriel K; Adelman MA; Lyden SP
    Circulation; 2019 Oct; 140(14):1145-1155. PubMed ID: 31567024
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Stellarex drug-coated balloon for treatment of femoropopliteal arterial disease-The ILLUMENATE Global Study: 12-Month results from a prospective, multicenter, single-arm study.
    Schroë H; Holden AH; Goueffic Y; Jansen SJ; Peeters P; Keirse K; Ito W; Vermassen F; Micari A; Blessing E; Jaff MR; Zeller T
    Catheter Cardiovasc Interv; 2018 Feb; 91(3):497-504. PubMed ID: 29086462
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-Term Clinical Effectiveness of a Drug-Coated Balloon for the Treatment of Femoropopliteal Lesions.
    Laird JA; Schneider PA; Jaff MR; Brodmann M; Zeller T; Metzger DC; Krishnan P; Scheinert D; Micari A; Wang H; Masters M; Tepe G
    Circ Cardiovasc Interv; 2019 Jun; 12(6):e007702. PubMed ID: 31195825
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The IN.PACT DEEP Clinical Drug-Coated Balloon Trial: 5-Year Outcomes.
    Zeller T; Micari A; Scheinert D; Baumgartner I; Bosiers M; Vermassen FEG; Banyai M; Shishehbor MH; Wang H; Brodmann M;
    JACC Cardiovasc Interv; 2020 Feb; 13(4):431-443. PubMed ID: 32081236
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Durability of Treatment Effect Using a Drug-Coated Balloon for Femoropopliteal Lesions: 24-Month Results of IN.PACT SFA.
    Laird JR; Schneider PA; Tepe G; Brodmann M; Zeller T; Metzger C; Krishnan P; Scheinert D; Micari A; Cohen DJ; Wang H; Hasenbank MS; Jaff MR;
    J Am Coll Cardiol; 2015 Dec; 66(21):2329-2338. PubMed ID: 26476467
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment Effect of Drug-Coated Balloons Is Durable to 3 Years in the Femoropopliteal Arteries: Long-Term Results of the IN.PACT SFA Randomized Trial.
    Schneider PA; Laird JR; Tepe G; Brodmann M; Zeller T; Scheinert D; Metzger C; Micari A; Sachar R; Jaff MR; Wang H; Hasenbank MS; Krishnan P;
    Circ Cardiovasc Interv; 2018 Jan; 11(1):e005891. PubMed ID: 29326153
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Outcomes and Comparative Analysis of the Initial Results of Standard Balloon Angioplasty Versus Drug-Coated Balloons Alone Versus in Association With Laser-Excimer Atherectomy in the Treatment of Femoropopliteal Artery In-Stent Restenosis (INTACT).
    Ducasse E; Sapoval M; Brunet J; Commeau P; Goueffic Y; Sabatier J; Steinmetz E; Lermusiaux P; Rosset E; Caradu C
    J Endovasc Ther; 2024 Apr; ():15266028241248333. PubMed ID: 38659343
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Five-Year Outcomes of Post-Drug-Coated Balloon Angioplasty Dissection in Complex Femoropopliteal Artery Disease.
    Ren H; Liu J; Zhang J; Zhuang B; Fu W; Wu D; Wang F; Zhao Y; Guo P; Bi W; Wang S; Guo W
    Int J Gen Med; 2021; 14():4197-4207. PubMed ID: 34385840
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Drug-Coated Balloon vs Standard Percutaneous Transluminal Angioplasty for the Treatment of Atherosclerotic Lesions in the Superficial Femoral and Proximal Popliteal Arteries: One-Year Results of the MDT-2113 SFA Japan Randomized Trial.
    Iida O; Soga Y; Urasawa K; Saito S; Jaff MR; Wang H; Ookubo H; Yokoi H;
    J Endovasc Ther; 2018 Feb; 25(1):109-117. PubMed ID: 29264999
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Three-Year Results of the IN.PACT SFA Japan Trial Comparing Drug-Coated Balloons With Percutaneous Transluminal Angioplasty.
    Soga Y; Iida O; Urasawa K; Saito S; Jaff MR; Wang H; Ookubo H; Yokoi H
    J Endovasc Ther; 2020 Dec; 27(6):946-955. PubMed ID: 32865145
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Drug-Coated Balloon Angioplasty Versus Standard Uncoated Balloon Angioplasty for Long Femoropopliteal Lesions: Post Hoc Analysis of the 24-Month Results of the AcoArt I Study.
    Jia S; Liu J; Sun G; Zhang J; Zhuang B; Jia X; Fu W; Wu D; Wang F; Zhao Y; Guo P; Bi W; Wang S; Guo W;
    Ann Vasc Surg; 2022 May; 82():70-80. PubMed ID: 34902474
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Drug-coated balloon versus standard percutaneous transluminal angioplasty for the treatment of superficial femoral and popliteal peripheral artery disease: 12-month results from the IN.PACT SFA randomized trial.
    Tepe G; Laird J; Schneider P; Brodmann M; Krishnan P; Micari A; Metzger C; Scheinert D; Zeller T; Cohen DJ; Snead DB; Alexander B; Landini M; Jaff MR;
    Circulation; 2015 Feb; 131(5):495-502. PubMed ID: 25472980
    [TBL] [Abstract][Full Text] [Related]  

  • 19. German Center Subanalysis of the LEVANT 2 Global Randomized Study of the Lutonix Drug-Coated Balloon in the Treatment of Femoropopliteal Occlusive Disease.
    Scheinert D; Schmidt A; Zeller T; Müller-Hülsbeck S; Sixt S; Schröder H; Weiss N; Ketelsen D; Ricke J; Steiner S; Rosenfield K
    J Endovasc Ther; 2016 Jun; 23(3):409-16. PubMed ID: 27117972
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sustainable Antirestenosis Effect With a Low-Dose Drug-Coated Balloon: The ILLUMENATE European Randomized Clinical Trial 2-Year Results.
    Brodmann M; Werner M; Meyer DR; Reimer P; Krüger K; Granada JF; Jaff MR; Schroeder H;
    JACC Cardiovasc Interv; 2018 Dec; 11(23):2357-2364. PubMed ID: 30522663
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.